Industry Focus

It's a battle of the big bio's on this episode of Industry Focus Healthcare. Is Gilead Sciences finally overcoming its hep C headwind? Is Amgen beating back biosimilars? We dig into the details as we discuss which of these biopharma behemoths delivered better first quarter results. Stocks: GILD, AMGN

Check out more of our content here:

Direct download: 20190515_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EDT